Evidence map›Paper›PMID 16328383›Full record

ArticleCancer immunology, immunotherapy : CII2006

Characterization of the gammadelta T cell response to acute leukemia.

Paul F Meeh, Michelle King, Rebecca L O'Brien, Stephanie Muga, Philip Buckhalts, Ronnie Neuberg, Lawrence S Lamb

Abstract read
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. The Graft-Versus-Leukemia Effect in AML.Frontiers in oncology · 2019
    Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Cytotoxic and regulatory properties of circulating Vδ1+ γδ T cells: a new player on the cell therapy field?Molecular therapy : the journal of the American Society of Gene Therapy · 2014
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Paul F MeehDepartment of Pediatrics, University of South Carolina School of Medicine, Columbia, SC, 29203, USA.
Michelle King
Rebecca L O'Brien
Stephanie Muga
Philip Buckhalts
Ronnie Neuberg
Lawrence S Lamb

Funding

ANTILEUKEMIC EFFECT OF GAMMA/DELTA T CELLSR21CA076667 · NCI · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI LAMB, LAWRENCE S · 2000 to 2001
$235k
NCI NIH HHS R21 CA 76667
6 · The paper itself

Abstract

backgroundPrevious work from our center has suggested a correlation between increased donor-derived Vdelta1+ gammadelta T cells and long-term relapse-free survival following bone marrow transplantation for leukemia. Questions remain, however, as to whether this observation can be explained by a gammadelta T cell-based immune response against primary leukemia.

methodsWe examined gammadelta T cell receptor (TCR) phenotype, cell proliferation, and cytolytic activity following culture with irradiated primary leukemia blasts from a haploidentical first-degree relative. Subsequently, we also studied the gammadelta TCR phenotype and complimentarity determining region 3 (CDR3) cDNA sequences from 17 newly diagnosed leukemia patients.

resultsIn 17/28 (61%) of in vitro cultures, gammadelta T cells proliferated in culture with primary blasts. Vdelta1+ T cells were proportionally increased in all cultures and were the predominant cell population in 6/17. In the 7 cultures where cytotoxicity could be assessed, 6 (86%) showed some degree of cytotoxicity to the primary leukemia. Vdelta1+ T cells were also the predominant gammadelta T cell subtype in pre-treatment leukemia patients principally due to loss of Vdelta2+ T cells rather than expansion of Vdelta1+ cells. The Vdelta1 CDR3-region cDNA sequence from these patients revealed exclusive use of the Jdelta1 constant region and sequence conservation in 4/11 patients.

conclusionsgammadelta T cells exhibit an in vitro response to primary leukemia blasts that is manifested by proliferation, an increased proportion of Vdelta1+ T cells, and cytotoxicity to the primary leukemia blasts. The Vdelta1+ T cell population is also predominant in newly diagnosed leukemia patients likely due to a loss of circulating Vdelta2+ T cells. A small proportion of newly diagnosed patients showed Vdelta1 CDR3 region similarity. These findings suggest a role for gammadelta T cells in the immune response to leukemia.

Indexed as

ImmunophenotypingBase SequenceCell ProliferationCells, CulturedComplementarity Determining RegionsCytotoxicity Tests, ImmunologicFemaleHumansLeukemia, Myeloid, AcuteLymphocyte Culture Test, MixedMaleMolecular Sequence DataPrecursor Cell Lymphoblastic Leukemia-LymphomaReceptors, Antigen, T-Cell, gamma-deltaSequence Analysis, DNASurvival RateComplementarity Determining RegionsReceptors, Antigen, T-Cell, gamma-delta

Identifiers

PMID16328383
PMCPMC11031079

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.